Quick Answer Box
- What the case is: Product liability and class action litigation against Dexcom Inc. alleging that the G7 continuous glucose monitor delivers inaccurate glucose readings that cause insulin dosing errors, hypoglycemic events, and serious patient injury.
- Who qualifies: Patients who used the Dexcom G7 CGM and suffered documented harm, including hypoglycemia, hyperglycemia crises, hospitalizations, or insulin overdose events directly traceable to device inaccuracy or sensor failure.
- What it may be worth: Individual personal injury claims in comparable medical device cases have resolved between $50,000 and $500,000+ depending on severity. Consumer protection class claims may yield smaller per-claimant recoveries.
Case Snapshot
| Detail | Information |
|---|---|
| Defendant | Dexcom Inc. (NASDAQ: DXCM), headquartered in San Diego, CA |
| Product at Issue | Dexcom G7 Continuous Glucose Monitor |
| Regulatory Class | Class II Medical Device, FDA 510(k) Clearance |
| Courts | U.S. District Courts, multiple jurisdictions; JPML consolidation status pending as of 2026 |
| MDL Number | No formal MDL established as of Q1 2026; individual and class filings active |
| Litigation Status | Active pre-certification; individual personal injury and class action consumer protection claims in parallel tracks |
| Adverse Events Filed | Thousands of entries logged in FDA MAUDE database across 2022 to 2025 |
| Settlement Fund | No global settlement announced as of Q1 2026 |
| Statute of Limitations | Varies by state: 2 to 4 years from date of injury (product liability) |
Introduction
The Dexcom G7 lawsuit problems now occupy a growing corner of the medical device litigation space. Patients with diabetes who relied on the G7 to guide insulin decisions are alleging that the device's sensor failures produced dangerously inaccurate glucose readings, with real consequences measured in emergency room visits and, in the most serious cases, permanent injury.
Dexcom Inc. brought the G7 to market in late 2022 after FDA 510(k) clearance. The device quickly became one of the most widely adopted continuous glucose monitors in the United States. Adoption was fast precisely because the G7 promised tighter accuracy and a smaller form factor than prior generations.
The volume of adverse event reports in the FDA MAUDE database, filed by patients, clinicians, and healthcare facilities, grew steadily through 2023 and 2024. Those reports form part of the evidentiary foundation plaintiffs' attorneys are building into formal legal claims.
As of early 2026, the litigation sits at a pivotal stage. No formal Multidistrict Litigation panel consolidation has been announced, but individual and putative class filings are active across multiple federal districts. Readers who believe they were harmed should understand both the legal theories in play and the state-specific deadlines that govern whether a claim remains viable.
Dexcom G7 Lawsuit Problems: What the Core Allegations Are
The dexcom g7 lawsuit problems center on one fundamental allegation: the device delivered glucose readings it could not verify were accurate, and patients made insulin decisions based on those readings.
Plaintiffs allege Dexcom knew or should have known the G7 sensor experienced accuracy degradation in specific physiological and environmental conditions. The failure modes alleged include rapid glucose change scenarios, pressure-induced sensor errors from sleeping on the device, and adhesion failures that caused partial sensor dislodgement without alerting the user.
The legal theories advanced are not limited to one claim type. Product liability claims assert design defect and failure to warn. Consumer protection claims assert that Dexcom's marketing accuracy representations exceeded what the device could reliably deliver in real-world conditions.
Key alleged problems:
- Sensor readings lagging actual blood glucose by 15 to 30 minutes during rapid glucose changes
- False "in range" readings during actual hypoglycemia
- Sensor adhesion failures causing undetected measurement voids
- Calibration drift during the latter portion of the 10-day wear period
- Missed high and low alerts in temperature-sensitive conditions
*Attorney Insight: Attorneys handling these claims point to the gap between Dexcom's published Mean Absolute Relative Difference (MARD) accuracy statistics and the real-world adverse event pattern in the MAUDE database as a central evidentiary tension.*
Dexcom G7 Lawsuit Update 2026: Where the Litigation Stands
As of Q1 2026, the dexcom g7 lawsuit update shows active litigation without a resolved global settlement. This places the case in a familiar early-to-mid stage medical device litigation posture.
No JPML order has consolidated these cases into a single MDL, though plaintiffs' firms have been evaluating whether to petition. The volume of filed cases and the geographic spread across multiple districts make consolidation a logical next step if filings continue to accumulate.
Dexcom has not issued a formal product recall as of this writing. The company has released software and algorithm updates, which plaintiffs characterize as post-sale remediation that implicitly acknowledges prior performance shortfalls.
2026 Litigation Timeline Snapshot:
| Period | Development |
|---|---|
| 2022 Q4 | FDA 510(k) clearance; commercial launch of G7 |
| 2023 | MAUDE adverse event reports accelerate; early legal inquiries |
| 2024 | First individual personal injury complaints filed in federal courts |
| 2025 | Putative class action filings added; plaintiff firms expand intake |
| Q1 2026 | Active pre-certification litigation; no MDL, no global settlement |
| 2026 ongoing | Discovery disputes; potential JPML petition under evaluation |
*Attorney Insight: Attorneys handling these claims point to the pre-consolidation stage as both an opportunity and a risk for claimants: earlier individual filings can position plaintiffs favorably ahead of any MDL bellwether selection.*
Litigation Watch: As of early 2026, the Dexcom G7 litigation is active across multiple federal districts without MDL consolidation, individual settlement, or a confirmed global resolution fund.
Dexcom G7 Class Action Lawsuit: How That Track Works
The dexcom g7 class action lawsuit track runs parallel to individual personal injury claims, and the two tracks are legally distinct.
A class action consolidates claims from many plaintiffs with common questions of law and fact. For the G7 litigation, the class track primarily advances consumer protection and warranty theories. The argument is that all purchasers were misled by accuracy representations that could not be uniformly fulfilled.
Class certification requires satisfying the Rule 23 requirements under federal civil procedure. Numerosity, commonality, typicality, and adequacy of representation must all be established before a class is certified and the case can proceed on a class-wide basis.
Class action vs. individual claim comparison:
| Factor | Class Action Track | Individual Personal Injury |
|---|---|---|
| Primary legal theory | Consumer protection, warranty | Product liability, negligence |
| Typical payout per claimant | Lower ($500 to $5,000 range) | Higher ($50,000 to $500,000+) |
| Injury proof required | Purchase and misrepresentation | Documented physical harm |
| Who benefits most | All purchasers, even without injury | Patients with serious documented harm |
| Current status | Putative (pre-certification) | Active individual filings |
*Attorney Insight: Attorneys handling these claims point to the importance of clients understanding that participation in a class settlement often extinguishes the right to pursue a separate, higher-value individual injury claim.*
Dexcom G7 Sensor Failure Lawsuit: The Mechanics of What Went Wrong
The dexcom g7 sensor failure lawsuit is grounded in how the electrochemical glucose sensing technology actually operates and where it can fail.
The G7 uses a subcutaneous electrochemical sensor coated with glucose oxidase enzyme. Current generated by the enzyme reaction is translated into a glucose reading. Any condition that interferes with this reaction or with the signal transmission can produce an inaccurate reading.
Plaintiffs' technical experts are expected to argue that Dexcom's sensor manufacturing tolerance and quality control processes permitted devices with substandard enzyme coating distribution to reach patients. They will also argue that the algorithm used to smooth and present readings masked transient inaccuracy events rather than flagging them.
Reported sensor failure categories in MAUDE filings:
- Signal loss without user notification
- Readings diverging from fingerstick confirmations by more than 20 percent
- Premature sensor failure before the 10-day wear period ended
- Sensor body separation from adhesive backing during wear
- Incorrect low glucose alarms (false alarms and missed alarms both reported)
*Attorney Insight: Attorneys handling these claims point to manufacturing batch records and quality control documentation as among the most critical discovery targets in sensor-defect litigation.*
Dexcom G7 Accuracy Problems Lawsuit: The MARD Data Problem
The dexcom g7 accuracy problems lawsuit is built, in part, on the disconnect between Dexcom's published accuracy metrics and adverse event reality.
Dexcom reported a MARD of approximately 8.2 percent for the G7 in its FDA submission, a figure representing average deviation from reference blood glucose measurements. This figure was obtained in a controlled clinical trial with compliant, screened participants.
Real-world use introduces variables the clinical trial excluded: physical activity, perspiration, dehydration, rapid glucose excursions, and sensor placement variation. Plaintiffs argue that Dexcom's commercial marketing applied the clinical MARD figure to real-world performance claims without adequate qualification.
MARD comparison across CGM devices (approximate, based on FDA submissions):
| Device | Published MARD | Regulatory Class |
|---|---|---|
| Dexcom G7 | ~8.2% | Class II, 510(k) |
| Dexcom G6 (predecessor) | ~9.0% | Class II, 510(k) |
| Abbott FreeStyle Libre 3 | ~7.8% | Class II, 510(k) |
| Medtronic Guardian 4 | ~8.7% | Class II, 510(k) |
*Attorney Insight: Attorneys handling these claims point to the distinction between controlled-setting MARD and real-world accuracy as a recurring battleground in CGM litigation, with the gap being most consequential for patients managing Type 1 diabetes with aggressive glycemic targets.*
Litigation Watch: The accuracy representation gap between Dexcom's clinical MARD figures and real-world sensor performance forms the technical backbone of both the class action misrepresentation theory and individual product defect claims.
Dexcom G7 False Readings Injuries: What Patients Experienced
The dexcom g7 false readings injuries documented in legal filings and FDA reports range from near-miss insulin miscalculations to hospitalizations.
False low readings prompted some patients to consume carbohydrates unnecessarily, spiking blood glucose. More dangerous were false high readings that led patients or automated insulin pumps to deliver excess insulin, causing hypoglycemic events. Severe hypoglycemia can produce seizures, loss of consciousness, cardiac events, and in extreme cases, death.
Among the injury categories appearing most frequently in MAUDE submissions and plaintiff complaints:
Documented injury types:
- Severe hypoglycemia requiring emergency intervention
- Hypoglycemic seizure attributed to insulin overdose following false high reading
- Diabetic ketoacidosis (DKA) events following missed high alerts
- Falls and fractures during hypoglycemic confusion
- Hospitalization for glucose destabilization without prior device alert
- In the most severe cases, hypoglycemia-related cardiac events
*Attorney Insight: Attorneys handling these claims point to the causal chain between device inaccuracy and insulin dosing as the medical causation argument most critical to surviving a motion to dismiss: they must connect the device reading to the specific dosing decision to the specific injury.*
Dexcom G7 FDA Complaints: The Regulatory Record
The dexcom g7 FDA complaints entered into the MAUDE database represent the public regulatory record that plaintiffs' attorneys mine for pattern evidence.
The MAUDE system requires manufacturers, importers, and device facilities to report events where a device may have caused or contributed to serious injury or death. Voluntary patient and clinician reports supplement mandatory reports.
As of late 2025, the Dexcom G7 had accumulated thousands of adverse event entries in MAUDE. The volume of entries places the G7 in the high-complaint tier of Class II devices. Dexcom's mandatory reports to the FDA also include its own characterization of events, which plaintiffs use to show the company was on notice of recurring failure patterns.
Categories of MAUDE complaint types reported for the Dexcom G7:
| Complaint Category | Significance in Litigation |
|---|---|
| Device inaccuracy (reading error) | Core defect allegation |
| Failure to alarm | Failure to warn sub-theory |
| Sensor adhesion failure | Manufacturing defect evidence |
| Software/algorithm error | Design defect evidence |
| Injury: hospitalization reported | Damages foundation |
| Injury: death reported | Highest-value individual claims |
*Attorney Insight: Attorneys handling these claims point to the date stamps on manufacturer-filed MAUDE reports as critical to establishing when Dexcom's legal notice of the problem arose, which directly affects punitive damages arguments.*
Dexcom G7 Injuries Reported: The Severity Spectrum
The dexcom g7 injuries reported across legal filings and FDA submissions span a wide severity spectrum, which directly maps onto the damages range for individual claims.
At the lower end, patients report stress, disrupted diabetes management, and out-of-pocket costs from finger-prick confirmations they were told the G7 would make unnecessary. At the higher end, families report ER admissions, ICU stays, and deaths they attribute to the device's failure to alert during acute hypoglycemia.
The most legally significant cases are those with documented medical records showing a clear sequence: G7 reading, patient or caregiver action, acute medical event. Attorneys call this the causation chain, and without it, the case is substantially harder to win.
Injury severity tiers and litigation value:
| Severity Tier | Description | Estimated Claim Value Range |
|---|---|---|
| Tier 1 (Economic only) | Out-of-pocket costs, no physical injury | $1,000 to $10,000 |
| Tier 2 (Minor injury) | ER visit, hypoglycemia, rapid recovery | $25,000 to $75,000 |
| Tier 3 (Moderate injury) | Hospitalization, short-term sequelae | $75,000 to $200,000 |
| Tier 4 (Severe injury) | ICU, seizure, cardiac event, long-term harm | $200,000 to $500,000+ |
| Tier 5 (Wrongful death) | Death attributed to device failure | $500,000 to multi-million |
*Attorney Insight: Attorneys handling these claims point to complete medical records from the injury event as the single most important document a potential claimant can preserve, ideally including the G7 device data log from around the time of the event.*
Litigation Watch: The Dexcom G7 injury reports span a wide severity spectrum, and individual claim value is closely tied to documented injury severity, with wrongful death cases representing the highest-value claims in this litigation.
Dexcom G7 Recall Lawsuit: Is There a Recall and Does It Matter?
The dexcom g7 recall lawsuit framing requires clarification: Dexcom has not issued a Class I or Class II voluntary or FDA-mandated recall of the G7 as of early 2026.
Dexcom has issued software updates and fielded what the company describes as product performance improvements. In litigation, plaintiffs will argue that these updates constitute post-sale acknowledgment of known defects. Defendants typically argue updates reflect normal product improvement, not defect admission.
The absence of a formal recall does not bar product liability claims. Courts apply the same negligence, strict liability, and warranty frameworks regardless of whether the manufacturer formally recalled the product. Recall is a regulatory designation. Liability is a legal determination.
What a recall status means for litigation:
| Recall Status | Effect on Product Liability Claim |
|---|---|
| No recall issued | Claim still viable; defect proved through other evidence |
| Class II recall (minor risk) | Supports defect allegation; limited damages signal |
| Class I recall (serious risk) | Strong defect support; significant damages signal |
| Voluntary recall pre-litigation | May accelerate settlement pressure |
*Attorney Insight: Attorneys handling these claims point to the regulatory distinction between recall and safety communication as important: a company issuing a "safety alert" without triggering formal recall classification still creates notice evidence useful in litigation.*
Who Qualifies for Dexcom G7 Lawsuit: Core Eligibility Requirements
Who qualifies for the dexcom g7 lawsuit depends on which legal track a potential claimant pursues: individual personal injury or consumer class action.
For the personal injury track, qualification generally requires documented use of the Dexcom G7, an identifiable device malfunction or accuracy failure, and a resulting physical injury with medical records to support it. Claims without a documented physical harm are significantly harder to value and litigate.
For the consumer protection class action track, the eligibility bar is lower. Purchase of the G7 device and exposure to Dexcom's accuracy marketing representations may be sufficient, even without a documented physical injury.
Eligibility comparison by claim type:
| Eligibility Factor | Personal Injury Track | Class Action Track |
|---|---|---|
| G7 device used | Required | Required |
| Device malfunction documented | Strongly preferred | Helpful but not required |
| Physical injury occurred | Required | Not required |
| Medical records of harm | Required | Not required |
| Purchase documentation | Helpful | Required |
| Prescription documentation | Helpful | Helpful |
*Attorney Insight: Attorneys handling these claims point to the importance of not assuming the class action track is the right choice simply because it's easier to qualify for: the damages differential is substantial, and patients with serious injuries should pursue individual claims.*
Dexcom G7 Lawsuit Eligibility Criteria: A State-by-State Consideration
The dexcom g7 lawsuit eligibility criteria are shaped not only by what happened, but where the plaintiff lives and where the case is filed.
State product liability law varies significantly across the country. Some states follow strict liability doctrine, meaning plaintiffs need not prove negligence, only that the product was defective and caused harm. Other states require negligence proof. States including California, New York, and Illinois offer plaintiff-friendly product liability frameworks.
States with statutory caps on non-economic damages present a different calculation. A patient who suffered documented but non-economic harm (pain and suffering, emotional distress) in a cap state may recover substantially less than an identically injured patient in a non-cap state.
State law variables affecting eligibility and recovery:
| Factor | Example States (Favorable) | Example States (Restrictive) |
|---|---|---|
| Strict liability doctrine | CA, NY, IL, PA | Varies by state interpretation |
| No non-economic damage cap | CA, NY, IL | OH, TX, FL (caps apply) |
| Long statute of limitations | CA (3 yrs), NY (3 yrs) | KY (1 yr), TN (1 yr) |
| Comparative fault approach | Pure comparative (CA, NY) | Contributory negligence (MD, NC) |
*Attorney Insight: Attorneys handling these claims point to choice-of-law analysis as a critical early step in evaluating multi-state claimants, particularly for plaintiffs who purchased in one state and were injured in another.*
Dexcom G7 Product Liability Claim: The Three Legal Theories
The dexcom g7 product liability claim can be built on three distinct theories, and attorneys typically plead all three in the alternative.
Design defect argues the G7's fundamental sensor design was flawed from the outset. The product, as designed, carried an unreasonable risk of inaccuracy that a reasonable alternative design would have avoided. This is the hardest theory to prove but produces the broadest liability exposure for Dexcom.
Manufacturing defect argues that specific units left the production line out of specification, even if the design itself was sound. Batch record discovery, quality control documentation, and device serial number tracing are essential to this theory.
Failure to warn argues Dexcom did not adequately disclose known accuracy limitations in its labeling, patient instructions, or marketing materials. This theory is frequently the most survivable at the motion to dismiss stage because it relies on what the company said and omitted, not just what the device did.
Three-theory liability breakdown:
| Theory | What Must Be Proved | Strength |
|---|---|---|
| Design defect | Flawed design; safer alternative existed | Hardest; broadest exposure |
| Manufacturing defect | Specific unit out of spec | Requires batch data |
| Failure to warn | Inadequate warnings; knew of risk | Most common survivor at MTD |
*Attorney Insight: Attorneys handling these claims point to failure to warn as the most frequently litigated theory in medical device cases because it ties company knowledge directly to patient harm, without requiring the plaintiff to redesign the device on paper.*
Litigation Watch: Product liability claims against Dexcom are advancing on three parallel theories, with failure to warn frequently cited as the strongest at early litigation stages due to its direct connection to the company's communications record.
Dexcom G7 Lawsuit Settlement Amount: What the Numbers Could Look Like
The dexcom g7 lawsuit settlement amount is not yet established because no global resolution has been reached as of Q1 2026.
Settlement projections in medical device litigation are informed by comparable cases. The Medtronic insulin pump litigation, the Abbott CGM-related claims, and prior Dexcom G5 accuracy-related matters all provide benchmarks. Those benchmarks suggest individual serious injury claims in this category settle in ranges from $50,000 to well above $500,000 for severe, well-documented harm.
Class action consumer settlements in medical device cases typically yield per-claimant recoveries in the $500 to $5,000 range, with attorneys' fees consuming a negotiated percentage of the common fund.
Comparable medical device settlement benchmarks:
| Case Category | Typical Individual Range | Class/Aggregate |
|---|---|---|
| CGM accuracy-related claims | $50,000 to $200,000+ | $500 to $3,000 per class member |
| Insulin pump defect claims | $75,000 to $500,000+ | $1,000 to $5,000 per class member |
| Wearable device failure (general) | $25,000 to $150,000 | $250 to $2,500 per class member |
| Wrongful death (device-related) | $500,000 to multi-million | N/A |
*Attorney Insight: Attorneys handling these claims point to the lack of a global settlement fund as a reason claimants with strong individual injury cases should not wait for a class resolution that may deliver far less than their individual claim warrants.*
Dexcom G7 Lawsuit Payout: Factors That Determine Individual Recovery
The dexcom g7 lawsuit payout for an individual claimant depends on a set of factors that courts and insurers evaluate systematically.
The severity of physical injury is the dominant factor. Documented hospitalizations, permanent complications, and ongoing medical costs all increase payout potential. Economic damages, including medical bills and lost wages, are calculable and easier to prove than non-economic damages like pain and suffering.
Causation clarity matters as much as injury severity. A claimant who can show the exact sequence of G7 misreading, insulin dosing action, and acute medical event has a substantially stronger case than one whose records are incomplete or ambiguous.
Individual payout calculation factors:
- Medical expenses: Documented, past and projected future costs
- Lost income: Wages, earning capacity reduction
- Pain and suffering: Non-economic, state-cap dependent
- Permanency: Ongoing medical need elevates damages
- Causation strength: Direct link to device reading increases value
- Comparative fault: Patient's own conduct may reduce award in some states
- Punitive damages: Available if Dexcom's conduct is proved to have been willful
*Attorney Insight: Attorneys handling these claims point to the availability of punitive damages as a litigation lever: if discovery produces internal Dexcom communications showing awareness of the accuracy gap before product launch, the damages calculus shifts substantially.*
Dexcom G7 Lawsuit How to File: The Legal Process Step by Step
The process for filing a dexcom g7 lawsuit how to file inquiry requires understanding that this is not a simple online form submission.
Product liability and personal injury claims against Dexcom must be filed in a court of competent jurisdiction, either in state court or federal court depending on the parties' citizenship and the amount in controversy. Cases involving diverse parties and claims exceeding $75,000 qualify for federal jurisdiction under 28 U.S.C. Section 1332.
The practical first step is retaining a plaintiff's product liability attorney. Most reputable firms handling medical device litigation take these cases on a contingency fee basis, meaning no upfront cost to the claimant. The attorney will evaluate the case, preserve evidence, and file the complaint.
Filing process sequence:
- Document all device use: sensor lot numbers, wear dates, app data exports
- Preserve all medical records from the injury event and surrounding period
- File a MAUDE report with the FDA (optional but adds to the regulatory record)
- Consult a product liability attorney with medical device litigation experience
- Retain the attorney; sign a contingency fee agreement
- Attorney investigates and files the complaint in the appropriate jurisdiction
- Defendant serves an answer; discovery begins
- Case proceeds to settlement negotiations or trial
*Attorney Insight: Attorneys handling these claims point to the preservation of Dexcom app data as a step many claimants inadvertently skip: the app stores sensor reading logs that can corroborate exactly what the device displayed at the time of the injury.*
Dexcom G7 Lawsuit Deadline: Statutes of Limitations by State
The dexcom g7 lawsuit deadline is one of the most time-sensitive elements in this entire body of litigation.
Product liability statutes of limitations vary by state and begin running from different trigger points. Most states use either the date of injury or the date the plaintiff discovered (or should have discovered) that the device caused the harm. The discovery rule can extend the filing window, but it is not available in every state.
Missing the statute of limitations extinguishes the claim permanently. Courts rarely grant exceptions. This is not an area where claimants should wait.
Statute of limitations by key state (product liability):
| State | Limitations Period | Discovery Rule |
|---|---|---|
| California | 2 years from discovery | Yes |
| New York | 3 years from injury | Limited |
| Texas | 2 years from injury | Yes |
| Florida | 2 years from discovery | Yes |
| Illinois | 2 years from injury | Yes |
| Pennsylvania | 2 years from injury | Yes |
| Ohio | 2 years from injury | Yes |
| Georgia | 2 years from injury | Yes |
| Tennessee | 1 year from injury | Limited |
| Kentucky | 1 year from injury | Yes |
*Attorney Insight: Attorneys handling these claims point to the Tennessee and Kentucky one-year windows as the most critical to flag for claimants in those states, where even a modest delay in consulting counsel can permanently bar an otherwise viable claim.*
Litigation Watch: Statutes of limitations in product liability cases are unforgiving: claimants in states like Tennessee and Kentucky have as little as one year from the date of injury to file, and courts grant virtually no exceptions after that window closes.
Dexcom G7 Attorney: What Kind of Lawyer Handles This Case
Selecting the right dexcom g7 attorney means identifying counsel with specific medical device product liability experience, not simply a general personal injury practice.
Medical device litigation requires attorneys who can retain and examine biomechanical and biomedical engineering experts, navigate FDA regulatory submissions as evidence, and handle complex discovery involving corporate quality management systems. The cases are expensive to develop and typically funded by the law firm under contingency arrangements.
The firms most actively handling Dexcom G7 claims as of 2026 are those already positioned in the mass tort and medical device space, with infrastructure for multi-plaintiff litigation. A solo practitioner without this background is less equipped for the discovery demands of a case like this.
Attorney selection criteria for Dexcom G7 claims:
| Qualification | Why It Matters |
|---|---|
| Medical device litigation experience | FDA regulatory records require specialist fluency |
| In-house or retained medical experts | Expert testimony required on causation and defect |
| Mass tort infrastructure | Case volume requires organized plaintiff management |
| Contingency fee representation | No upfront cost; attorney shares litigation risk |
| Multi-district litigation experience | If MDL forms, familiarity with the process matters |
| Track record with CGM or diabetes device cases | Prior relevant verdicts inform strategy |
*Attorney Insight: Attorneys handling these claims point to the importance of asking prospective counsel specifically about their expert witness network for biomedical engineering and endocrinology, as these two disciplines are typically the pillars of the liability and causation case.*
Frequently Asked Questions
What are the main Dexcom G7 lawsuit problems that form the basis of legal claims?
The core problems are sensor inaccuracy causing false glucose readings, failure to alert patients during actual hypoglycemia or hyperglycemia, and adhesion failures that created undetected measurement gaps.
These failures led patients to make insulin dosing decisions based on incorrect information, causing serious physical harm in documented cases.
Has Dexcom recalled the G7 because of these problems?
Dexcom has not issued a formal product recall of the G7 as of early 2026.
The absence of a recall does not bar legal claims: product liability standards apply independently of whether a manufacturer formally recalls a device.
Who qualifies for the Dexcom G7 lawsuit in 2026?
For personal injury claims, qualification requires documented G7 use, an identifiable sensor failure or inaccurate reading, and a resulting physical injury supported by medical records.
For consumer class action claims, purchase of the device and exposure to Dexcom's accuracy marketing representations may be sufficient even without physical injury.
How much can someone get from a Dexcom G7 lawsuit?
Individual personal injury settlements in comparable medical device cases range from approximately $50,000 to over $500,000, depending on injury severity, causation clarity, and state law.
Consumer class action participants typically recover far less, often in the $500 to $5,000 range per claimant, from any common settlement fund.
What is the deadline for filing a Dexcom G7 lawsuit?
The deadline depends on the state: most product liability statutes of limitations run 1 to 3 years from the date of injury or discovery of harm.
Tennessee and Kentucky impose only a one-year window, making consultation with an attorney immediately time-critical for claimants in those states.
What type of attorney should someone hire for a Dexcom G7 claim?
A plaintiff's product liability attorney with specific medical device litigation experience is the appropriate professional for this type of claim.
The attorney should have experience with FDA regulatory records as evidence, in-house or retained biomedical engineering experts, and a contingency fee structure that requires no upfront payment from the claimant.
Closing
The Dexcom G7 litigation is not a speculative legal theory. It is an active, multi-district body of claims grounded in a documented record of adverse events, measurable accuracy gaps, and specific patient injuries. The legal theories are established. The regulatory record exists. The courts are open.
The statute of limitations clock is the most immediately consequential factor for anyone reading this in 2026. A claim that existed today may not exist in twelve months in certain states.
Speaking with a product liability attorney who handles medical device cases is the concrete next step. Most will evaluate the claim without charge and take the case on a contingency basis if the facts support it. The consultation costs nothing. Waiting may cost everything.
